Invega Trinza

Paliperidone palmitate

3-mth inj for maintenance treatment of schizophrenia in adults who have been adequately treated w/ 1-mth paliperidone palmitate inj for at least 4 mth.

IM Inj once every 3 mth, may be adjusted every 3 mth in increments of 175-525 mg based on tolerability &/or efficacy. Mild renal impairment Max recommended dose: 350 mg.

Hypersensitivity to paliperidone or risperidone.

Not to be inj intravascularly, SC or in divided doses. Discontinue use if hypersensitivity reactions, tardive dyskinesia, extrapyramidal symptoms, NMS, clinically significant QT prolongation & drug‐induced leukopoenia/neutropoenia occur. Not to be used in dementia-related psychosis. Avoid use in congenital long QT syndrome, history of cardiac arrhythmias. Known CV or cerebrovascular disease, conditions predisposing to hypotension; Parkinson's disease, dementia w/ Lewy bodies; history of seizures or conditions lowering seizure threshold; dysphagia; psychotic illnesses; hyperprolactinaemia; history of clinically significant low WBC; risk of factors for VTE; priapism; body temp regulation; hyperglycaemia & DM; wt gain. Intraoperative floppy iris syndrome. Antiemetic effect. Avoid use in combination w/ class IA or III antiarrhythmics, antipsychotics, antibiotics or drugs prolonging QT interval; alcohol. Concomitant use w/ risperidone; psychostimulants eg, methylphenidate. Avoid inadvertent inj into blood vessel. May affect ability to drive & operate machines. Not recommended in moderate or severe renal impairment. Hepatic impairment. Pregnancy. Not to be used during lactation. Not recommended in paed <18 yr. Elderly w/ dementia.

Anxiety, insomnia, agitation, schizophrenia; nasopharyngitis, URTI, UTI, flu; increased/decreased wt, increased blood glucose; headache, akathisia; irritability; cough; decreased appetite; depression; inj site pain & induration, fatigue; diarrhoea; hyperglycaemia; HTN. Parkinsonism, sedation/somnolence, tremor; tachycardia; nausea; increased transaminases; musculoskeletal & back pain; amenorrhea, menstrual disorder.

Increased bloodstream conc w/ risperidone. Emergence of extrapyramidal symptoms w/ psychostimulants eg, methylphenidate. Antagonized effect of l-dopa & other dopamine agonists. Additive effect w/ orthostatic hypotension-inducing drugs. Decreased mean steady-state C_max & AUC w/ carbamazepine. Increased C_max & AUC w/ divalproex Na. Drugs prolonging QT interval; other centrally-acting drugs; alcohol.

Antipsychotics

N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.

B